Oncogenic transcription factor Myc deregulates the cell cycle and simultaneously reprograms cellular metabolism to meet the biosynthetic and bioenergetic needs of proliferation. Myc also sensitizes cells to mitochondria-dependent apoptosis. Although metabolic reprogramming has been circumstantially connected to vulnerability to apoptosis, the connecting molecular pathways have remained poorly defined. Here, we show that Myc-induced altered glutamine metabolism involves ATP depletion and activation of the energy sensor AMP-activated protein kinase (AMPK), which induces stabilizing phosphorylation of p53 at Ser15. Under influence of Myc, AMPK-stabilized tumor suppressor protein p53 accumulates in the mitochondria and interacts with the protein complex comprised of B-cell lymphoma 2 (Bcl-2) antagonist/killer (BAK) and Bcl2-like 1 (Bcl-xL). Mitochondrial p53 induces conformational activation of proapoptotic Bak without disrupting the Bak-Bcl-x L interaction. Further liberation of Bak specifically from the p53-activated Bak-Bcl-x L complex leads to spontaneous oligomerization of Bak and apoptosis. Thus, Myc-induced metabolic changes are coupled via AMPK and phospho-p53 to the mitochondrial apoptosis effector Bak, demonstrating a cell-intrinsic mechanism to counteract uncontrolled proliferation.
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oncogene | cell death | cancer metabolism H ealthy cells coordinate the cell cycle and growth according to the supply of nutrients by slowing down the cell cycle under low supply. Oncogenic transcription factor Myc deregulates cell cycle independently of the extracellular nutrient status, and such cells rapidly succumb to apoptosis if deprived of glucose or, particularly, of glutamine (1) (2) (3) . The strict dependence of the viability of Myc overexpressing cells on excess glucose and glutamine has been attributed to Myc-induced metabolic reprogramming (metabolic transformation), which fuels autonomous patterns of cell proliferation and renders cells "addicted" to reprogrammed metabolic pathways (4) (5) (6) . However, the mechanisms coupling metabolic reprogramming and apoptotic machinery are poorly understood.
Glucose and glutamine are the main nutrients that cultured mammalian cells catabolize for energy production and biosynthesis (7) . Myc induces up-regulation of proteins responsible for glucose uptake and glycolysis (6, 8) . Moreover, Myc stimulates glutamine uptake and metabolism through regulation of glutamine transporters and glutaminase (GLS) (3, 9) . Deregulated Myc can divert glucose away from mitochondrial metabolism and reprogram metabolism toward using glutamine as the main oxidizable substrate for maintenance of the tricarboxylic acid cycle and ATP production (3, 9) . In addition to providing carbon for bioenergetic reactions, glutamine is also the obligate donor of nitrogen in biosynthesis of nucleic acids and the primary source of nitrogen for the synthesis of nonessential amino acids (4) . These changes in protein expression and nutrient utilization set the stage for Myc-induced reprogramming of cell metabolism, which on the whole is seen as a molecular adaptation to the high proliferation rate of cancerous cells. A fundamental feature of cancer cell-associated metabolic programs is inefficient ATP production (7), and also Myc-mediated metabolic reprogramming has been associated with depletion of cellular ATP levels (2) . B-cell CLL/lymphoma 2 (Bcl-2) and Bcl2-like 1 (Bcl-x L ) suppress the glutamine starvation-mediated apoptosis, which indicates involvement of the mitochondrial apoptosis pathway (2, 3) .
The cellular energy status is sensed by AMP-activated protein kinase (AMPK), which monitors shifts in the cellular AMP/ADP to ATP ratio. The kinase activating signals come from declining ATP and increasing AMP and ADP levels, resulting in the AMP and ADP bound active heterotrimeric AMPK complex (10) (11) (12) . In normal physiological conditions, active AMPK dynamically reprograms ATP generating and consuming processes so as to restore ATP levels in the cell (5) . However, the classical view that AMPK acts only as a biochemical toggle switch between ATP-consuming anabolic and ATP-producing catabolic processes is changing as recent findings have provided evidence that AMPK also coordinates cell proliferation with availability of carbon sources and participates in apoptosis (13, 14) . Under low glucose conditions, AMPK induces phosphorylation of tumor suppressor protein p53 at serine 15, which mediates AMPK-dependent cell cycle arrest (13) . However, in thymocytes and tumor cells, low glucose induces AMPK and p53-dependent apoptosis (14) .
In addition to nutrient deprivation, Myc renders cells sensitive to the apoptotic action of death receptor ligands and diverse stress signals such as limited growth factor supply or hypoxia (15) (16) (17) . Therefore, it is believed that Myc sensitizes cells to apoptosis via some general mechanism, which promiscuously renders cells sensitive to different triggers of apoptosis. Bcl-2 and Bcl-x L efficiently inhibit Myc-induced apoptosis, which mechanism is often crucial for progression of Myc-driven tumorigenesis (16) . Bcl-2 and Bcl-x L together with myeloid cell leukemia sequence 1 (Mcl-1) and BCL2-related protein A1 (A1) form a group of antiapoptotic Bcl-2 family members, which antagonize proapoptotic multidomain Bcl-2 family members BCL2-antagonist/killer (Bak) and Bcl-2-associated X protein (Bax). In healthy cells, Bak and Bax exist as globular monomeric proteins comprised of nine α-helices buried in the protein structure. Apoptotic stimuli induce a series of conformational rearrangements, which expose the N terminus (including α1 helix), the Bcl-2 homology domain 3 (BH3) domain (α2), and, specifically in Bax, the mitochondrial outer membrane anchoring domain (α9) (18) . Exposed BH3 domain binds to the hydrophobic surface groove on another member, which produces Bak or Bax homodimers. These homodimers have competence to further assemble into pore-forming oligomers, which contributes to mitochondrial outer membrane permeabilization (MOMP) and leads to lethal activation of effector caspases (18, 19) . However, the BH3:groove interaction can also take place with antiapoptotic Bcl-2 family members, which blocks apoptosis by preventing formation of Bak and Bax homo-oligomers (18) . Implementation of Myc-induced apoptosis requires Bak and Bax although the specific requirement for effector may vary from one cell type to another (20) (21) (22) . The third category of Bcl-2 family proteins includes proapoptotic BH3-only family members such as BH3 interacting domain death agonist (Bid), Bcl-2-like 11 (Bim), and Bcl-2-binding component 3 (Puma), which are activators of Bak and Bax. The activators generally act by neutralizing antiapoptotic Bcl-2 proteins via BH3:groove interactions, and, in addition, a subset of BH3-only proteins can directly activate Bak and Bax (23) (24) (25) .
Besides the Bcl-2 family, a central element in the Myc-induced apoptotic program and roadblock for Myc-induced tumorigenesis is the tumor suppressor protein p53 (17) . Multifunctional p53 has different ways to engage into Myc-driven apoptotic programs. For example, in lymphoid cells, Myc transcriptionally up-regulates tumor suppressor protein ARF to induce E3 ubiquitin-protein ligase Mdm2 (HDM2 in humans) routed p53 stabilization (26) . Further downstream, p53 can mediate apoptosis via transcription-dependent mechanisms, which involve up-regulation of proapoptotic proteins, or transcription-independent mechanisms, and both pathways can interact with the mitochondrial apoptosis pathway (27) . The transcription-independent p53 pathways of apoptosis have been attributed to translocation of stabilized p53 to mitochondria, where p53 can directly interact with Bak, Bax, and antiapoptotic Bcl-2 family members (28, 29) . Acute Myc activation induces conformational activation of Bak but not morphological apoptosis in nontransformed human mammary epithelial MCF10A cells (20) . Nonetheless, Bak is required for the apoptotic function of Myc in these cells. Here, we establish that conformational activation of Bak is a specific marker of the sensitized mitochondrial apoptosis pathway. Our investigations of the molecular underpinnings mediating Mycinduced conformational activation of Bak show that deregulation of Myc changes the cellular ADP/ATP ratio and leads to AMPK activation, which induces ser15 phosphorylation and mitochondrial accumulation of p53. Mitochondrial phospho-p53 functionally reorganizes the Bak-Bcl-x L complex and activates Bak. This study exposes a surprisingly direct molecular pathway coupling Myc-induced metabolic reprogramming via AMPK and p53 to mitochondrial apoptotic machinery, thus defining a framework for understanding tumor cell vulnerabilities in the context of transformation-specific metabolic alterations.
Results

Conformationally Altered Bak Is a Distinct Marker of Apoptosis
Sensitized Cells. Activation of Myc sensitizes mammary epithelial cells to apoptosis, which occurs concomitantly with N-terminal exposure of Bak in the mitochondria ( Fig. 1 and Fig. S1 ) (20) . Bak is also a central mediator of Myc-dependent apoptosis in these cells (Fig. S1 A-G) (20) . We wished to determine whether antiapoptotic Bcl-2 family members control the conformational status of Bak and lentivirally silenced Bcl-x L , Mcl-1, and A1 in MCF10A cells expressing a conditionally active, tamoxifen inducible Myc fusion protein (MycER) (Fig. S1H) . Silencing of Bcl-x L , but not the two other proteins, induced spontaneous Bak activation independently of Myc ( Fig. 1 A and  B) . We also found that overexpression of Bcl-x L prevents the Myc-induced conformational activation of Bak ( Fig. 1 C and D) . To determine whether Bcl-x L controls conformational status of Bak via physical interaction, we neutralized Bcl-x L with ABT-737. ABT-737 is a pharmacological small molecule that blocks the BH3-binding surface groove in Bcl-2, Bcl-x L , and Bcl2-like 2 (Bclw) (but not in Mcl-1) (30) . Like Myc, ABT-737 also induced conformational activation of Bak and sensitized cells to death receptor pathway inducing TNF-related apoptosis inducing ligand (TRAIL) (Fig. 1E) . We observed conformational activation of Bax only in the cell populations undergoing morphological apoptosis, which association we have reported earlier (20) . ABT-737 generally promoted conformational activation of Bak in a wide variety of cell lines, including breast cancer cell lines and other epithelial cell types ( analysis, we observed prominent formation of high-order oligomers of Bak and Bax in the cell populations induced to undergo apoptosis (Fig. 1H) . However, neither Myc nor ABT-737 alone was sufficient to trigger Bak or Bax oligomerization (Fig. 1H) .
The results establish Bcl-x L -controlled conformational Bak activation as a distinct marker of the sensitized mitochondrial apoptosis pathway, contrasting with conformational Bax activation present only in dying populations of mammary epithelial cells.
Myc Induces Stabilization and Mitochondrial Accumulation of p53.
The results raised the possibility that Myc-induced conformational activation of Bak involves dissociation of the Bak-Bcl-x L interaction or downmodulation of Bcl-x L expression. However, Myc activation did not alter Bcl-x L expression or Bak-Bcl-x L interaction in MCF10A cells (Fig. 2A) . As expected, ABT-737 dissociated Bak from Bcl-x L but not from Mcl-1 ( Fig. 2A) . We concluded that Myc activates Bak via an alternative mechanism acting upstream of the Bak-Bcl-x L interaction.
Bak has around 30 interaction partners [Protein Interaction Network Analysis (PINA)] including p53, which is an established mediator of Myc-dependent apoptosis. We found that activation of Myc significantly elevates p53 levels in the mitochondria and cytosol (Fig. 2B) . Myc did not affect p53 mRNA levels (Fig. S1J ), but the Myc-induced mitochondrial p53 was strongly phosphorylated at the N-terminal Ser15 site (Fig. 2C) . Phosphorylation of this N-terminal site prevents p53 from interacting with its negative regulator Mdm2, therefore stabilizing p53 (31, 32) . We further investigated whether Myc might also induce stabilizing phosphorylation of p53 in the epithelial cells of mouse mammary gland. Tissue sections were obtained for analyses from a transgenic mouse strain harboring whey acidic protein (WAP)-controlled MYC allele (33) . In this strain, lactogenic hormones activate WAP-Myc in luminal epithelial cells during late pregnancy, and the allele remains active thereafter (34) . Stimulation of WAP-Myc by multiple rounds of pregnancies leads to development of hyperplasia in all glands and solitary adenocarcinomas, generally appearing in one or two glands (33, 35) . Phospho-Ser18 p53 (Ser18 is equal to human Ser15) antibody was validated for use in immunohistochemistry ( Fig. S1 K and L), and tumor-free (hyperplastic) and tumor-bearing mammary glands from parous mice were analyzed for phospho-Ser18 p53 status. Samples from the control wild-type mice were negative for cytosolic phospho-Ser18 p53 staining. In contrast, tumor-free WAPMyc glands widely expressed cytosolic phospho-p53 ( Fig. 2 D and  E) . Surprisingly, mammary tumors derived from the same mice showed no staining with phospho-p53 antibody. The differences in phospho-p53 status are not attributable to the proliferative rate of cells ( Fig. 2F and Fig. S1M ). The results indicate that Myc induces cytosolic stabilization and accumulation of p53 in the mammary epithelial cells and tissue. However, this pathway appears to be compromised in fully developed carcinomas.
Mitochondrial Accumulation of p53 Activates Bak. We next asked whether a chemical stabilization of p53, in the absence of oncogene signaling, would be sufficient to induce conformational Bak activation. A small molecule Nutlin-3a prevents Mdm2 from recognizing p53 and consequently stabilizes p53 (36) . Addition of Nutlin-3a to MCF10A cells induced Ser15 phosphorylation as well as mitochondrial, cytosolic ( (Fig. 3D) .
DNA damage induces a well-defined pathway for p53 stabilization via DNA-activated protein kinase (DNA-PK), Ataxia telangiectasia mutated kinase (ATM), ataxia telangiectasia and Rad3 related (ATR), and checkpoint kinase 2 (CHK2). These DNA damage response kinases phosphorylate N-terminal sites of p53 followed by dissociation of p53 from Mdm2, nuclear accumulation of p53, and induction of repair and cell cycle regulatory genes (32) . We investigated whether the DNA damage-induced nuclear p53 pathway induces conformational activation of Bak. Administration of DNA-damaging drugs Etoposide or Doxorubicin led to a nucleoplasmic accumulation of Ser15 phosphorylated p53 [hereafter, p-p53 (S15)], up-regulation of mRNA encoding GADD45 (growth arrest and DNA-damage-inducible) and mRNA for p53-induced glycolysis and apoptosis regulator TIGAR and accumulation of cyclin-dependent kinase inhibitor protein p21, all of which are established p53 targets (Fig. 3 E, F , H, and I and Fig. S2F ). In addition to nuclear p53 response, DNA damage also induced mitochondrial accumulation of p53 (Fig.  S2G) . Nonetheless, DNA damage failed to induce conformational Bak activation (Fig. 3G) . Notably, activation of Myc did not induce nucleoplasmic accumulation of p53 or p-p53 (S15) (Fig. 3 E  and F and Fig. S2F ). Furthermore, active Myc did not lead to upregulation of any of the examined transcriptional targets of p53 ( Fig. 3 H and I) . These results altogether establish a tight link between the mitochondrial accumulation of p53 and conformational activation of Bak but also demonstrate that mitochondrial accumulation of p53 does not autonomously activate Bak.
We next asked whether p53 is required for Myc-induced Bak activation and found that siRNA-mediated silencing of p53 reduces Myc's ability to activate Bak in several cell types (Fig. S2 H-J) . Furthermore, Myc was completely unable to induce conformational activation of Bak in MCF10A cells rendered p53null by zinc finger nuclease approach (MCF10A p53null-MycER cells; Fig. 3 J and K) . We reconstituted wild-type (WT) p53 expresssion in MCF10A p53null-MycER cells and found that WT p53 rescues Myc's ability to induce conformational Bak activation (Fig. 3K) . Interestingly, p53
QS transactivation-deficient mutant also rescued Myc-induced Bak activation (Fig. 3K) . The results show that transactivation-deficient p53 can convey Myc's apoptotic signal to Bak. intensively studied by cell biological, biophysical, and structural approaches. In contrast to relatively stable interaction between p53 and Bcl-x L , it is widely held that p53 interacts with Bax and Bak via transient molecular interaction (28, (37) (38) (39) (40) . However, unstable protein interactions are difficult to detect by methods requiring cell lysis, such as coimmunoprecipitation (co-IP) analysis. Therefore, we analyzed the physical proximity of p53 and Bak in situ by using quantitative proximity ligation assay (PLA). PLA revealed a colocalization of N-terminally exposed Bak and p53 in the cells with active Myc (Fig. 4 A and B) . The colocalization signal was strongly enhanced in apoptotic conditions. p53 has higher affinity for Bcl-x L than for Bak (40) , and the endogenous p53-Bcl-x L interaction has been detected by co-IP analysis in various cells (37) . Also in mammary epithelial cells, p53 coimmunoprecipitated with Bcl-x L (Fig. 4C) . Surprisingly, activation of Myc significantly diminished the interaction between p53 and Bcl-x L , and ABT-737 fully disrupted the complex (Fig.  4C) . Moreover, TRAIL-induced apoptosis in sensitized cells led to dissociation of p53 from Bcl-x L . The results were corroborated with three different p53 antibodies used in co-IP analysis (Fig. 4 C and D and Fig. S2 K and L) . Taken together, our results suggest that activation of Myc alters the steady-state interactions of p53 with Bak and Bcl-x L . In mammary epithelial cells, p53 acquires a proximal position next to conformationally activated Bak and becomes less tightly bound to Bcl-x L .
The described action of p53 is reminiscent of allosteric regulation because p53 seems to promote conformational activation of Bak outside of the active site (BH3:groove). To determine whether p53-induced Bak activation in fact promotes apoptosis, we disrupted the BH3:groove interaction by ABT-737 in the absence or presence of conditions inducing mitochondrial accumulation of p53. Strikingly, ABT-737 treatment induced activation of Bax, which indicates full activation of the mito- (Fig. 4E) . The results suggest that mitochondrial accumulation of p53 promotes the apoptotic properties of Bak even when it stays bound to Bcl-x L . A schematic model for the altered interactions of p53 with the Bak-Bcl-x L complex and functional consequences is shown in Fig. S3N .
Myc Induces p53-Bak Pathway via AMPK. To further elucidate the mechanisms by which Myc induces p53 stabilization and conformational Bak activation, we used chemical inhibitors targeting most of the kinases linked to Ser15 phosphorylation of p53 (41) . The compounds were analyzed for their ability to perturb Mycinduced Bak activation and p53 stabilization. None of the inhibitors targeting DNA damage response kinases could prevent activation of Bak (Fig. 5A) . However, we found that compound C, an ATP competitive inhibitor of AMPK (42), specifically prevents the Myc-induced activation of Bak (Fig. 5 A and B) . Inhibition of AMPK, phospho Acetyl-CoA carboxylase (p-ACCSer79) serving as a marker of inhibition (see below), also prevented Myc-induced Ser15 phosphorylation of p53 and consequent stabilization and accumulation of p53 in the cytosol and mitochondria (Fig. 5 C and D) . Pharmacological AMPK activation with an AMP analog aminoimidazole carboxamide ribonucleotide (AICAR) induced Ser15 phosphorylation of p53 (Fig. 5C ), establishing that active AMPK does phosphorylate p53 at Ser15 in mammary epithelial cells. These and earlier (Fig. 3) findings suggest that Myc does not induce p53 and Bak activation via cellular DNA damage response but, instead, via AMPK activation-coupled metabolic effects. promoting the activating phosphorylation of Thr172 in the activation loop of AMPK, whereas ATP has the opposite effect (11) . Therefore, we explored whether Myc alters the cellular energy status. Activation of Myc decreased cellular ATP levels and concomitantly increased ADP levels ( Fig. 6A and Fig. S2M ), changing the intracellular ADP/ATP ratio (Fig. 6B ). This change in ADP/ATP ratio was coincident with prominent increase in Ser15 phosphorylation of p53 and activating Thr-172 phosphorylation of the catalytic subunit AMPKα (Fig. 6C) . Active AMPK inhibits anabolic reactions, for example repressing de novo synthesis of fatty acids by inhibitory phosphorylation of the rate-limiting enzyme Acetyl-CoA carboxylase (ACC). Therefore, phospho ACC signal is a widely used biomarker of AMPK activity (43) . In keeping with the Myc-induced AMPK activity in epithelial cells, we detected inactivating Ser79 phosphorylation of ACC (Fig. 6C) . Moreover, we determined phospho ACC status in the mammary glands of WAP-Myc mice and found that the Myc-induced hyperplastic mammary epithelium was strongly positive for phospho-Ser79 ACC (Fig.   6D ). The control glands from parous mice were mainly negative for phospho ACC (Fig. 6D) . The Myc-induced adenocarcinomas were scored positive although the staining intensity was weaker than in the hyperplasia. The results consistently demonstrate Myc-dependent AMPK pathway activation in vitro and in vivo.
We determined whether Myc-induced AMPK signaling affects the glutaminolytic pathway because mitochondrial glutaminolysis fuels Myc-driven cell growth and proliferation programs. As reported earlier in other cell types, also in mammary epithelial cells Myc elevated the expression of GLS and rendered cells addicted to glutamine (Fig. 6 E and F) . Interestingly, the Mycinduced elevated GLS expression was completely dependent on AMPK activity (Fig. 6E) , suggesting that AMPK activity controls Myc's ability to reprogram metabolic pathways.
Next, we investigated whether AMPK contributes to the onset of mitochondrial apoptosis. We induced Myc-dependent apoptosis with TRAIL or DNA damaging agents and observed that chemical inhibition of AMPK efficiently blocks conformational activation of Bak and apoptosis (Fig. 6 G-I) . We also asked whether a pharmacological activation of AMPK would be sufficient to induce mitochondrial accumulation of p53 and conformational activation of Bak. For these experiments, we used AICAR and compound A769662, the latter of which is a specific and direct pharmacological activator of AMPK (44) . Administration of AICAR or A769662 to mammary epithelial cells induced activation of the AMPK pathway, stabilizing Ser15 phosphorylation of p53, and conformational activation of Bak (Figs. 6 J and K and Fig. S2 N-Q) . Moreover, when AICAR or A769662 was added together with TRAIL, the combination treatment synergistically induced apoptosis (Fig. 6K and Fig. S2 P and R) .
Finally, to determine how generally Myc triggers activation of the AMPK pathway, phospho p53, and Bak, we introduced MycER into several different wild-type p53-expressing epithelial cell lines, including nonmammary epithelial types. Fig. 7 and Fig.  S3 A-M summarize the overall impact of Myc on AMPK, p53, and Bak effectors in nine different epithelial cell lines, in a fibroblast cell line, and in the mammary gland. We found that Myc triggers activation of both AMPK and p53 in most (7/10) of the examined cell lines. Myc-induced conformational activation of Bak was detected in half of the cell lines (5/10), and Nutlin was slightly more efficient, inducing Bak activation in 8 cell lines.
In summary, our data reveal AMPK as a central mediator of the oncogene-induced reprogramming of metabolic and apoptotic machineries (Fig. 8) .
Discussion
Myc-induced up-regulation of GLS and further addiction to the glutaminolytic pathway are hallmarks of Myc-induced metabolic transformation, which adapts cells to meet the bioenergetic and biosynthetic demands of increased cell proliferation. Here, we show that Myc-induced metabolic transformation of mammary epithelial cells is accompanied by cellular ATP depletion, change in the ADP/ATP ratio, and activation of AMPK. We find that AMPK activity is needed to maintain the Myc-induced GLS expression, implying that AMPK activity may contribute to the viability of transformed cells. Paradoxically, Myc-induced AMPK activity is also particularly important for the onset of the apoptotic cell program, which involves AMPK-mediated phosphorylation of p53 at Ser15, stabilization and mitochondrial accumulation of p53, altered interactions between phospho-p53 and the Bak-Bcl-x L complex, and conformational activation of Bak. Therefore, Mycinduced AMPK activity has a surprising dual role in regulating the prosurvival glutaminolytic pathway and mitochondrial apoptotic signaling (Fig. 8) .
Previous results have demonstrated that, in primary fibroblast culture, glucose deprivation-induced AMPK activity mediates Ser15 phosphorylation and consequent stabilization of p53, leading to cell cycle arrest (13) . These observations have given rise to the concept that AMPK-p53 signaling mediates a metabolic cell cycle checkpoint, which halts the cell cycle in response to low extracellular carbon supply (13) . In human tumor cells, glucose deprivation also triggers AMPK activation, which induces p53-dependent cell death (14) . Importantly, these observations and indications that even transient decreases in ATP concentration can trigger apoptosis (45, 46) have suggested that AMPK also mediates apoptosis in response to metabolic stress. However, currently there are no general frameworks defining the molecular pathways and biological or pathological context for metabolic stress-induced AMPK activation, p53 stabilization, and consequent apoptotic response.
The apoptotic activity of p53 has often been associated with signaling cascades triggered by extensive cell damage, for example, DNA damage or mitotic catastrophe (32, 47) . However, our findings reveal that the metabolic induction of p53-dependent apoptosis uses an alternative, direct molecular pathway involving AMPK-mediated Ser15 phosphorylation and mitochondrial accumulation of p53 tethered to conformational activation of Bak. We note that, although our results demonstrate Ser15 phosphorylation mediated stabilization of p53, they do not exclude the possibility that other posttranslational mechanisms contributed to the mitochondrial accumulation of p53.
The AMPK-dependent apoptotic mechanism may in extreme circumstances control physiological cell death, for example, if ATP levels fall critically low. However, this form of apoptosis may be rare in healthy cells where AMPK activity can quickly replenish ATP levels by inhibiting anabolic reactions and activating catabolic reactions (10, 43) . Oncogenic Myc deregulates cell cycle independently of the nutrient availability, and dividing cells require constant anabolic metabolism, at the expense of ATP production, 1 MCF7 cells are lacking caspase-3. Apoptosis quantified with active Bax (Fig. S1G) 2 Myc sensitizes ZR-75-30 cells to autophagic or necrotic cell death (Fig. S3B) 3 Myc-dependent sensitization of MRC5-hT cells to TRAIL-induced apoptosis described in (1). 4 Myc activation by lactogenic hormones in 3D cultures of WAP-Myc mouse mammary epithelial cells renders cells sensitive to apoptosis (2) . WAP-Myc mammary glands express p-ACC (Fig. 6D ) and p-p53 (Fig. 2D) . for macromolecule synthesis and production of biomass (48) . Therefore, Myc-promoted anabolic metabolism accompanied by low ATP content may lead to chronic AMPK activation, which we observed in the mammary glands of WAP-Myc mice. It is therefore conceivable that AMPK-induced Ser15 phosphorylation, stabilization, and mitochondrial accumulation of p53 is a transient and relatively harmless event for healthy cells but will compromise the long-term viability of transformed cells by apoptotic sensitization. Therefore, we propose that the apoptosis sensitizing AMPK-p53-Bak pathway may act as an intrinsic tumor suppressor mechanism and may constitute an important module in the metabolic tumor suppressor network involving AMPK and its regulators (43) . The results show that Myc-induced mitochondrial accumulation of p53 promotes the apoptotic properties of Bak without disrupting the BH3:groove interaction between Bak and Bcl-x L . Instead, according to our study, the critical sensitization step involves phospho p53-mediated conformational activation of Bak, which occurs in molecular arrangement allowing close proximity of these proteins. A schematic model for apoptosissensitizing interactions between p53 and Bak-Bcl-x L complex is presented in Fig. S3N . We also show that mitochondrial accumulation of phospho p53 cooperates with dissociation of the BH3:groove interaction in induction of apoptosis. Therefore, it appears that the p53-induced molecular rearrangement of the Bak-Bcl-x L complex activates not only conformationally but also functionally apoptotic properties of Bak. Earlier investigations have shown that, in systems involving recombinant proteins and synthetic membranes or cell fractions, recombinant p53 induces N-terminal exposure and oligomerization of Bak and Bax, as well as cytochrome c release (29, 49) . These studies have demonstrated an interaction between Bak and p53, and the results have advocated a model that p53 acts in a similar manner as BH3-only proteins, which liberate apoptotic effectors from the antiapoptotic Bcl-2 family members. However, the model has been criticized because available structural studies suggest that p53 interacts with the acidic "underside" of Bcl-x L that is a separate domain from the hydrophobic binding groove formed by BH1, BH2, and BH3 (50). Our studies describe that the status of mitochondrial p53 is functionally coupled to the apoptotic properties of the Bak-Bcl-x L complex already before the events inducing liberation of Bak from Bcl-x L . Therefore, we suggest an allosteric type of activation mechanism for the Bak-Bcl-x L complex, which would enable cooperative interactions between Bcl-2 family members and nonmembers such as p53 (Fig. S3N) . We stress that the present observations in mammary epithelial cells do not preclude the possibility that in other cell types p53 induces apoptosis more directly than via described sensitization mechanism.
The present studies give mechanistic insight into the synthetic lethal interaction of Myc with a wide variety of different apoptotic pathways, a concept that has been perceived as an alternative to direct therapeutic targeting of Myc in cancer. We and others have observed over the past decades that Myc remarkably sensitizes cells to proapoptotic signals, which do not cause any obvious acute damage to the cells. However, many signals that are synthetically lethal with Myc activate BH3-only proteins, for example, death receptor signaling (Bid), growth factor deprivation (Bad), and targeted drugs (Bim) (15, 16) . Because deregulation of Myc induces metabolic transformation almost universally in cells, we believe that AMPK activation and downstream mitochondria-targeted p53 signaling form an important axis for apoptotic sensitization. The allosteric activation model for p53-mediated sensitization of the Bak-Bcl-x L complex (Fig. S3N) provides a plausible framework to explain apoptotic cooperation between AMPK-mitochondrial p53 signaling and diverse BH3-only proteins in induction of apoptosis. However, our results also show evidence that Myc does not exclusively sensitize cells to apoptosis via Bak in all cell types. Myc may activate in some cells to redundant mechanisms involving Bax or other apoptotic effector proteins (21) . The role of Myc-induced AMPK activity in such apoptotic responses, which are not coupled to conformational activation of Bak, remain to be clarified.
Finally, frequent deregulation of Myc expression (51) and relatively low mutation rate in p53 (52) , as well as the expression of cytosolic wild-type p53, have been observed in invasive breast cancer (53) , warranting future studies on predicted patterns of metabolic drug sensitivities in in vivo mammary tumor progression models.
Materials and Methods
Biological Materials. The cells, mouse strains, and protocols are described in SI Materials and Methods. All experiments involving animals were approved by the National Animal Ethics Committee of Finland. The mice were maintained according to the protocols of the Experimental Animal Committee of the University of Helsinki.
Reagents and Antibodies. A complete list of genetic reagents, chemicals, and antibodies used in this study is provided in SI Materials and Methods. Protocols for shRNA design, cloning, lentiviral production, and transduction have been described previously by Nieminen et al. (20) and are available from the Biomedicum Functional Genomics Unit. The validated shRNA sequences are listed in SI Materials and Methods.
Genetic Analyses. Protocols and sequences for siRNA-mediated gene silencing, quantitative PCR, and site-directed mutagenesis are described in SI Materials and Methods.
Immunofluorescence Microscopy and Histological Procedures. Cultured cells were grown and treated on coverslips and fixed in 4% (vol/vol) paraformaldehyde. For immunostainings with conformational specific antibodies, cells were permeabilized with Saponin (20) . Otherwise, Triton-X permeabilization protocols were used. Fixed cells or paraffin-embedded, 3-μm-thick tissue sections were immunostained as described in SI Materials and Methods. Imaging was performed with microscopes and facilities (SI Materials and Methods) provided by the Biomedicum Imaging Unit of the University of Helsinki.
In Situ Proximity Ligation Assay. The assay was performed using the Duolink kit (Olink Bioscience) according to the manufacturer's protocol.
Mitochondria-enriched fractions and light membrane/cytosolic fractions were isolated by using the Mitochondria/Cytosol Fractionation Kit (Biovision). Fig. 8 . A model: Myc-induced altered metabolism activates AMPK and p53, which sensitizes the mitochondrial apoptosis pathway. Activation of Myc promotes metabolic transformation, which adapts cells to meet the biosynthetic and bioenergetic requirements of rapid cell proliferation. Metabolic transformation decreases cellular ATP levels, activating the cellular energy sensor AMPK. AMPK promotes catabolic mode of metabolism (phospho-ACC) and contributes to establishment of glutaminolytic pathway (GLS). These AMPK-mediated processes release carbon for bioenergetic reactions and provide glutamine-derived nitrogen for biosynthesis of nucleic acids and nonessential amino acids (4). However, AMPK also induces phosphorylation of p53 at Ser15, which stabilizes the protein and leads to mitochondrial accumulation of p53. At the mitochondrial surface, phospho-p53 adjoins and rearranges the Bak-Bcl-x L complex (Fig. S3N) , resulting in conformational activation of Bak and apoptotic sensitization. This mechanism may act as a failsafe mechanism against cells with an inability to recover from energy stress, for example, due to oncogene-enforced cell cycle progression.
Cells were collected into ice-cold PBS, pelleted, and homogenized by using Dounce homogenizer. Nuclear and cytosolic fractions were separated with the Nuclear/Cytosol Fractionation Kit (Biovision).
Chemical Cross-Linking. Total lysates were cross-linked with the cysteine crosslinking reagent BMH, followed by isolation of mitochondria-enriched cell fractions (SI Materials and Methods) for analyses.
Coimmunoprecipitation Assays. Cells were lysed in 2% (wt/vol) CHAPS lysis buffer, and immunoprecipitation was performed as described in SI Materials and Methods using the Catch and Release v2.0 Reversible Immunoprecipitation System kit (Millipore).
Metabolic Assays. Cellular ATP and ADP levels levels were analyzed in cells seeded on 96-well plates with the luminescence-based EnzyLight kit (ELDT-100; BioAssay Systems) according to the manufacturer's protocol. Glutamine dependence of cells was analyzed by seeding cells to L-glutamine-free MCDB 170 media (US Biological). For controls, media were resupplemented with 2 mM L-glutamine. liberates Bak, which can proceed to form pore-forming homo-oligomers. The present data argue that mechanisms converting Bak into an oligomerization competent conformer also involve p53-mediated activation of Bak, which occurs when Bak is still bound to Bcl-x L . p53 acts as an allosteric activator of Bak rather than a BH3-only domain-like antagonist of Bcl-x L. According to the model (N1), in mammary epithelial cells, Bak, Bcl-x L , and p53 form an inactive protein complex on the mitochondrial surface. In the inactive complex, p53 and Bak bind Bcl-x L via distinct interaction sites (1), Bak adopts closed conformation, and Bak is sequestered via BH3:groove interaction by Bcl-x L . (N2) Chemical dissociation of Bak from the inactive protein complex is not sufficient to trigger autonomous oligomerization of Bak. (N3) Mitochondrial accumulation of Ser15 phosphorylated, stabilized p53 leads to conformational activation of Bak within the Bak-Bcl-x L complex. In the "activated" complex, p53 resides in close proximity to open Bak conformer and has reduced affinity to Bcl-x L. (N4) Exposure of p53-activated Bak-Bcl-x L complex to chemicals or proteins that disrupt the BH3:groove interaction leads to liberation and spontaneous oligomerization of Bak. The allosteric activation model suggests that p53-induced functional activation of Bak is an independent event of the dissociation of BH3:groove interaction, which may explain synthetic lethal interactions of the Myc-p53 pathway with BH3-only signaling. Circled P denotes phosphorylation, and double arrows mark reversible steps in the pathway. 
ACKNOWLEDGMENTS. We thank
